Free Trial
→ Ominous New Day in America (Get Ready for it) (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Roche Holding AG stock logo
RHHBY
Roche
$53.30
-1.4%		$54.97
$40.07
▼
$60.85
$339.55B0.452.24 million shs1.46 million shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$18.25
+4.3%		$19.10
$14.68
▼
$24.68
$1.93B0.383.05 million shs1.41 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Roche Holding AG stock logo
RHHBY
Roche
+2.89%+4.22%-1.63%+3.94%+19.76%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
+1.10%-3.95%-22.22%-14.72%-24.31%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Roche Holding AG stock logo
RHHBY
Roche
$53.30
-1.4%		$54.97
$40.07
▼
$60.85
$339.55B0.452.24 million shs1.46 million shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$18.25
+4.3%		$19.10
$14.68
▼
$24.68
$1.93B0.383.05 million shs1.41 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Roche Holding AG stock logo
RHHBY
Roche
+2.89%+4.22%-1.63%+3.94%+19.76%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
+1.10%-3.95%-22.22%-14.72%-24.31%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Roche Holding AG stock logo
RHHBY
Roche
2.50
Moderate Buy$60.0012.57% Upside
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1.95
Reduce$22.5923.77% Upside

Current Analyst Ratings Breakdown

Latest SRPT and RHHBY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetSector Perform$19.00 ➝ $17.00
10/5/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
10/5/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell$5.00
9/30/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$23.00 ➝ $20.00
9/28/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingUnderperform
9/24/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
9/23/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
9/10/2026
Roche Holding AG stock logo
RHHBY
Roche
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
9/9/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell
9/8/2026
Roche Holding AG stock logo
RHHBY
Roche
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
9/8/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 10/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Roche Holding AG stock logo
RHHBY
Roche
$76.45B4.44$3.65 per share14.60$7.18 per share7.42
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$2.20B0.88N/AN/A$10.89 per share1.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Roche Holding AG stock logo
RHHBY
Roche
$15.55BN/AN/A16.153.35N/AN/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-$713.41M-$2.90N/A13.620.27-13.48%-1.60%-0.66%11/4/2026 (Estimated)

Latest SRPT and RHHBY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$0.1355N/AN/AN/A$353.84 millionN/A
8/5/2026Q2 2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$0.2173$0.64+$0.4227-$0.05$366.39 million$401.25 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Roche Holding AG stock logo
RHHBY
Roche
$0.971.82%N/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Roche Holding AG stock logo
RHHBY
Roche
0.69
1.23
0.95
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.55
4.42
2.62

Institutional Ownership

CompanyInstitutional Ownership
Roche Holding AG stock logo
RHHBY
Roche
N/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%

Insider Ownership

CompanyInsider Ownership
Roche Holding AG stock logo
RHHBY
Roche
N/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
6.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Roche Holding AG stock logo
RHHBY
Roche
103,2496.37 billionN/ANot Optionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
835105.63 million98.34 millionOptionable

Recent News About These Companies

Royal Bank Of Canada Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price
October 8 at 10:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-royal-bank-of-canada-has-lowered-expectations-for-sarepta-therapeutics-nasdaq-srpt-stock-price-2026-10-08/
Jim Cramer Explains His Hesitation Over Sarepta (SRPT) Therapeutics
October 7 at 9:05 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/jim-cramer-explains-hesitation-over-212909919.html
Jim Cramer Explains His Hesitation Over Sarepta (SRPT) Therapeutics
October 7 at 7:31 PM  |  insidermonkey.comhttps://www.insidermonkey.com/news/jim-cramer-explains-his-hesitation-over-sarepta-srpt-therapeutics-1850554/
Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Lowered by Zacks Research
October 7 at 7:31 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31095960
Sarepta Therapeutics (NASDAQ:SRPT) Downgraded by Zacks Research to "Strong Sell"
October 7 at 7:29 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-sarepta-therapeutics-nasdaq-srpt-downgraded-by-zacks-research-to-strong-sell-2026-10-07/
HC Wainwright reiterates Sell for Sarepta Therapeutics stock
October 6 at 11:04 PM  |  ad-hoc-news.deA
Jim Cramer: This tech stock is 'very good,' Avery Dennison is a 'winner'
October 6 at 1:02 PM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/jim-cramer-this-tech-stock-is-very-good-avery-dennison-is-a-winner/ar-AA2dGtr9
Reviewing AbCellera Biologics (NASDAQ:ABCL) & Sarepta Therapeutics (NASDAQ:SRPT)
October 6 at 12:15 PM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31092776
Sarepta Therapeutics stock gets new ELEVIDYS data
October 5 at 3:10 PM  |  ad-hoc-news.deA
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
October 5 at 1:26 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20261005600508/en/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc.---srpt/
Sarepta Therapeutics (NASDAQ:SRPT) Given "Sell" Rating at HC Wainwright
October 5 at 8:06 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31086560
Sarepta Therapeutics' (SRPT) "Sell" Rating Reiterated at HC Wainwright
October 5 at 8:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-sarepta-therapeutics-srpt-sell-rating-reiterated-at-hc-wainwright-2026-10-05/
Sarepta Therapeutics: ELEVIDYS Data and Revenue Trends Support Continued Sell Rating with Unchanged $5 Price Target
October 5 at 7:11 AM  |  tipranks.comhttps://www.tipranks.com/news/ratings/sarepta-therapeutics-elevidys-data-and-revenue-trends-support-continued-sell-rating-with-unchanged-5-price-target-ratings-news?utm_source=marketbeat.com&utm_medium=referral
Consensus price target for Sarepta Therapeutics increased by 28.31% to MX$440.82
October 1, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/consensus-price-target-for-sarepta-therapeutics-increased-by-28-31-to-mx-440-82/ar-AA2dndBg
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS ...
October 1, 2026  |  marketscreener.comM
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 30, 2026
October 1, 2026  |  biospace.comB
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/sarepta-therapeutics-announces-inducement-grants-203000205.html
JPMorgan Chase & Co. Issues Pessimistic Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-jpmorgan-chase-co-issues-pessimistic-forecast-for-sarepta-therapeutics-nasdaq-srpt-stock-price-2026-09-30/
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
September 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/sarepta-therapeutics-presents-data-2026-123000754.html
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
September 30, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260930354567/en/Sarepta-Therapeutics-Presents-New-Data-at-2026-World-Muscle-Society-Annual-Congress-Demonstrating-Safety-and-Clinically-Meaningful-Functional-Benefit-of-ELEVIDYS-delandistrogene-moxeparvovec-in-Older-Ambulatory-Patients-with-Duchenne/
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sarepta Therapeutics (SRPT), BioNTech SE (BNTX) and AgomAb Therapeutics NV ADR (AGMB)
September 29, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/BNTX/pressreleases/4853697/analysts-have-conflicting-sentiments-on-these-healthcare-companies-sarepta-therapeutics-srpt-biontech-se-bntx-and-agomab-therapeutics-nv-adr-agmb/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Roche stock logo

Roche OTCMKTS:RHHBY

$53.30 -0.77 (-1.42%)
As of 03:54 PM Eastern

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

Sarepta Therapeutics stock logo

Sarepta Therapeutics NASDAQ:SRPT

$18.25 +0.75 (+4.29%)
Closing price 03:59 PM Eastern
Extended Trading
$18.22 -0.04 (-0.19%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas